Usefulness of bucindolol in congestive heart failure.

The sympathetic hyperactivity of congestive heart failure (CHF) may worsen cardiovascular function by down-regulation of myocardial beta-receptors. For this reason, beta blockade is proposed to be useful in CHF. Bucindolol is a new beta blocker that has intrinsic nonadrenergically-mediated vasodilation and may be valuable in treatment of CHF. To test this, 19 patients with CHF were randomized in a double-blind protocol to 3 months of treatment with bucindolol (n = 12) or placebo (n = 7). Significant improvement was seen in the bucindolol group using invasive and noninvasive tests; treadmill time increased from 445 to 530 seconds (p = 0.04), Minnesota Living With Heart Failure Questionnaire score improved from 61 to 40 (p = 0.0001), cardiac output increased from 4.0 to 4.7 (p = 0.02), and systemic vascular resistance decreased from 1,888 to 1,481 (p = 0.04). Also, peak exercise heart rate and pulmonary capillary wedge pressure decreased significantly with treatment. There were no changes in the placebo group. We conclude that bucindolol may be an effective treatment for CHF when administered chronically and that its nonadrenergic vasodilation may be an important feature.

RCT Entities:   Population Interventions Outcomes